PRMT5 and neoplasm: In glioblastoma, PRMT5 inhibition has been suggested to disrupt detained intron (DI) removal, whereas its effects on canonical alternative splicing, such as exon skipping in tumor growth genes, remain relatively minor (Braun et al, 2017).